Overview

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other injectable drugs. In this study, rHuPH20 combined with a non-preserved (NP) formulation of regular human insulin (INSULIN-PH20 NP) will be compared to insulin lispro with respect to absorption and action of insulin.

Phase:

Phase 2

Details

Lead Sponsor:

Halozyme Therapeutics

Treatments:

Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc